News
Q2 2025 Management View Steven O. Vondran, President and CEO, stated that "2025 continues to be a good year." He highlighted ...
Join Jeff Margolin of First Trust on CEF Insights for a 2025 midyear review of closed-end fund (CEF) performance and expert ...
Shipowners grapple with OPEC+ supply increases, tensions in the Middle East, and rising numbers of newbuildings.
The upgrade for emerging markets reflects a more optimistic outlook globally by the Fund, which nudged global GDP growth ...
Schneider adds that investors seem optimistic about American Tower due to stronger domestic organic growth heading into ...
Novo Nordisk lowers 2025 guidance as Wegovy and Ozempic face slower U.S. uptake, competition, and continued compounded GLP-1 ...
Pharma giant Novo Nordisk A/S (NYSE:NVO) is plunging 21% to trade at a nearly three-year low of $54.27, after the company's ...
The IMF on Tuesday raised its global growth forecasts for 2025 and 2026 slightly, citing stronger-than-expected purchases ...
3hon MSN
Discover AtriCure's standout Q2 2025 performance with 17% revenue growth, boosted by product innovation and international expansion.
The International Monetary Fund has revised India’s economic growth forecast upwards to 6.4% for both 2025 and 2026, citing a ...
Analysts William Tng and Tan Jie Hui believe Venture’s shares could find “support” at their FY2025 book value per share ...
Novo Nordisk has named Maziar Mike Doustdar, currently the company’s EVP of international operations, as the new CEO.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results